| Prev Close | 10.99 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 10.43 / 70.00 |
| Avg Volume | 782.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 38.56M |
| Market Cap | 427.48M |
| EPS | -4.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 706,672 share decrease in total short interest for Prothena Corp plc , to 4,748,273, a decrease of 12.95% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Prothena Corp plc , where a total of 1,475 contracts have traded so far, representing approximately 147,500 underlying shares. That amounts to about 57.7% of PRTA's average daily trading volume over the past month of 255,770 shares.
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,676,053 share decrease in total short interest for Prothena Corp plc , to 5,173,769, a decrease of 24.47% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.
Six charts showing signs of smart money footprints.
